Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

Five months af­ter their lead drug failed to treat schiz­o­phre­nia in a Phase III tri­al, Aca­dia is tout­ing just-bare­ly sig­nif­i­cant da­ta that sug­gest it could help im­prove a sub­set of the ill­ness’s symp­toms.

The 201 pa­tients giv­en Aca­dia’s Nu­plazid earned a -10.4 on the Neg­a­tive Symp­tom As­sess­ment-16 test, against a -8.5 score for the 202 place­bo pa­tients. The p-val­ue was 0.043, and the Phase II tri­al failed on the sec­ondary end­point: An­oth­er psy­cho­log­i­cal as­sess­ment called the Per­son­al and So­cial Per­for­mance (PSP).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER